.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
AstraZeneca
Teva
US Army
Moodys
Boehringer Ingelheim
QuintilesIMS
Daiichi Sankyo
Cerilliant
Chinese Patent Office

Generated: July 21, 2017

DrugPatentWatch Database Preview

HUMALOG MIX 50/50 Drug Profile

« Back to Dashboard

What is the patent landscape for Humalog Mix 50/50, and when can generic versions of Humalog Mix 50/50 launch?

Humalog Mix 50/50 is a drug marketed by Lilly and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in HUMALOG MIX 50/50 is insulin lispro protamine recombinant; insulin lispro recombinant. There are thirty-eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.

Summary for Tradename: HUMALOG MIX 50/50

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list187
Drug Prices:see details
DailyMed Link:HUMALOG MIX 50/50 at DailyMed

Pharmacology for Tradename: HUMALOG MIX 50/50

Ingredient-typeInsulin
Drug ClassInsulin Analog
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
HUMALOG MIX 50/50
insulin lispro protamine recombinant; insulin lispro recombinant
INJECTABLE;INJECTION021018-001Dec 22, 1999RXYesYes► Subscribe► Subscribe
Lilly
HUMALOG MIX 50/50 KWIKPEN
insulin lispro protamine recombinant; insulin lispro recombinant
INJECTABLE;INJECTION021018-002Sep 6, 2007RXYesYes7,291,132► SubscribeY ► Subscribe
Lilly
HUMALOG MIX 50/50 PEN
insulin lispro protamine recombinant; insulin lispro recombinant
INJECTABLE;INJECTION021018-003Dec 22, 1999DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: HUMALOG MIX 50/50

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly
HUMALOG MIX 50/50
insulin lispro protamine recombinant; insulin lispro recombinant
INJECTABLE;INJECTION021018-001Dec 22, 19995,461,031► Subscribe
Lilly
HUMALOG MIX 50/50
insulin lispro protamine recombinant; insulin lispro recombinant
INJECTABLE;INJECTION021018-001Dec 22, 19995,514,646► Subscribe
Lilly
HUMALOG MIX 50/50
insulin lispro protamine recombinant; insulin lispro recombinant
INJECTABLE;INJECTION021018-001Dec 22, 19995,747,642► Subscribe
Lilly
HUMALOG MIX 50/50
insulin lispro protamine recombinant; insulin lispro recombinant
INJECTABLE;INJECTION021018-001Dec 22, 19995,474,978► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Mallinckrodt
Colorcon
Cipla
McKinsey
Federal Trade Commission
Chinese Patent Office
US Department of Justice
Queensland Health
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot